| Literature DB >> 33414529 |
Darren Shu Jeng Ting1,2, Charlotte Shan Ho2, Rashmi Deshmukh2, Dalia G Said1,2, Harminder S Dua3,4.
Abstract
Corneal opacity is the 5th leading cause of blindness and visual impairment globally, affecting ~6 million of the world population. In addition, it is responsible for 1.5-2.0 million new cases of monocular blindness per year, highlighting an ongoing uncurbed burden on human health. Among all aetiologies such as infection, trauma, inflammation, degeneration and nutritional deficiency, infectious keratitis (IK) represents the leading cause of corneal blindness in both developed and developing countries, with an estimated incidence ranging from 2.5 to 799 per 100,000 population-year. IK can be caused by a wide range of microorganisms, including bacteria, fungi, virus, parasites and polymicrobial infection. Subject to the geographical and temporal variations, bacteria and fungi have been shown to be the most common causative microorganisms for corneal infection. Although viral and Acanthamoeba keratitis are less common, they represent important causes for corneal blindness in the developed countries. Contact lens wear, trauma, ocular surface diseases, lid diseases, and post-ocular surgery have been shown to be the major risk factors for IK. Broad-spectrum topical antimicrobial treatment is the current mainstay of treatment for IK, though its effectiveness is being challenged by the emergence of antimicrobial resistance, including multidrug resistance, in some parts of the world. In this review, we aim to provide an updated review on IK, encompassing the epidemiology, causative microorganisms, major risk factors and the impact of antimicrobial resistance.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33414529 PMCID: PMC8102486 DOI: 10.1038/s41433-020-01339-3
Source DB: PubMed Journal: Eye (Lond) ISSN: 0950-222X Impact factor: 3.775
Summary of the demographic factors and microbiological profiles of infectious keratitis in the literature published between 2010 and 2020, categorised into six distinct regions. Only studies that reported more than 500 cases are included.
| Year | Authors | Study period | Region | Total CS | Age (years) | Female (%) | Positive culture (%) | Organismsa | Microbiological profilesb | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| B (%) | F (%) | A (%) | |||||||||
| 2013 | Kaye et al. [ | 1995–2010 | Liverpool, UK | 2418 | – | – | 35.7 | 100 | 0 | 0 | CoNS (26.3); |
| 2017 | Tan et al. [ | 2004–2015 | Manchester, UK | 4229 | 45.9 | – | 32.6 | 90.6 | 7.1 | 2.3 | CoNS (24.4); |
| 2018 | Ting et al. [ | 2008–2017 | Sunderland, UK | 914 | 55.9 ± 21.0 | 52.1 | 46.1 | 91.0 | 4.2 | 4.8 | CoNS (25.9); |
| 2019 | Tavassoli et al. [ | 2006–2017 | Bristol and Bath, UK | 2614 | 47.7 ± 21.2 | 51.1 | 38.1 | 91.6 | 6.9 | 1.4 | CoNS (36.0); |
| 2020 | Ting et al. [ | 2007–2019 | Nottingham, UK | 1333 | 49.9 ± 22.2 | 49.6 | 37.7 | 92.8 | 3.0 | 4.2 | |
| 2017 | Tam et al. [ | 2000–2015 | Toronto, Canada | 2330 | 41.6 ± 24.0 | 53 | 57.3 | 86.0 | 4.9 | 2.2 | CoNS (37); |
| 2018 | Peng et al. [ | 1996–2015 | San Francisco, US | 2203 | – | – | 23.7 | 100 | 0 | 0 | |
| 2019 | Kowalski et al. [ | 1993–2018 | Pittsburgh, US | 1387 | – | – | 100 | 72.1 | 6.7 | 5.2 | |
| 2020 | Asbell et al. [ | 2009–2018 | US | 6091 | – | 46.8 | 100 | 100 | 0 | 0 | |
| 2011 | Cariello et al. [ | 1975–2007 | Brazil | 6804 | 42.1 ± 21.4 | 40 | 48.6 | 78.9 | 11.0 | 3.6 | CoNS (41.2); |
| 2013 | Marujo et al. [ | 2005–2009 | Brazil | 2049 | 45 | 45 | 71.6 | 80.3 | 7.0 | 6 | |
| 2015 | Hernandez-Camarena et al. [ | 2002–2011 | Mexico | 1638 | 45 | 51.4 | 38.0 | 88 | 12 | 0 | |
| 2016 | Yu et al. [ | 1975–2010 | Brazil | 859 | – | 42.1 | 40.3 | 100 | 0 | 0 | CoNS (23.8); |
| 2011 | Rautaraya et al. [ | 2006–2009 | India | 997 | – | 29.9 | 74.6 | 23.4 | 26.4 | 1.4 | |
| 2012 | Lin et al. [ | 2006–2009 | India | 5221 | – | – | 58 | 35.7 | 63.0 | 1.3 | |
| 2013 | Kaliamurthy et al. [ | 2005–2012 | India | 2170 | 45.7 ± 16.6 | 41.3 | 77 | 37.2 | 22.7 | 1.0 | |
| 2015 | Lalitha et al. [ | 2002–2012 | India | 23,897 | – | – | 59 | 24.7 | 34.3 | 2.2 | |
| 2015 | Wang et al. [ | 2013–2014 | China | 1000 | – | 31.8 | 53.5 | 0 | 100 | 0 | |
| 2016 | Hsiao et al. [ | 2003–2012 | Taiwan | 2012 | – | – | 49.3 | 81.1 | 16 | 1.1 | |
| 2017 | Zhang et al. [ | 2006–2015 | China | 6220 | 45.3 ± 22.1 | 40.6 | 18.2 | 100 | 0 | 0 | |
| 2018 | Khor et al. [ | 2012–2014 | Asia | 6626 | 46.0 | 39.2 | 70.7 | 38 | 32.7 | – | |
| 2019 | Acharya et al. [ | 2015–2017 | India | 1169 | – | – | 100 | 100 | 0 | 0 | CoNS (46.3); |
| 2019 | Lin et al. [ | 2010–2018 | China | 7229 | – | – | 42.8 | 52.7 | 57.6 | 0 | CoNS (28.6); |
| 2016 | Politis et al. [ | 2002–2014 | Israel | 943 | 47.0 ± 25.2 | 47 | 47.9 | 91.8 | 8.2 | 0 | CoNS (32.8); Pseudomonas (19.3); S. pneumonia (13.0) |
| 2019 | Cabrera-Aguas et al. [ | 2012–2016 | Sydney, Australia | 1084 | 54 | 48 | 66 | 100 | 0 | 0 | CoNS (45.8); |
| 2019 | Green et al. [ | 2005–2015 | Queensland, Australia | 3182 | 53 ± 22.6 | 47.6 | 73.6 | 93.1 | 6.3 | 0.6 | CoNS (33.9); |
CS corneal scrapes, CoNS coagulase negative staphylococci.
aBreakdown of organisms; B = Bacteria, F = Fungi, A = Acanthamoeba.
bThe three most common microorganisms isolated in the study.
cIncluded all types of ocular infection.
dIncluded all types of ocular infection but restricted to bacterial infection only.
Summary of risk factors and associated organisms of infectious keratitis in the literature published between 2010 and 2020, categorised into six distinct regions. Only studies that reported more than 200 cases are included.
| Year | Authors | Study period | Region | Patients | Age, years (Mean ± SD) | Female, % | Risk factors (%) |
|---|---|---|---|---|---|---|---|
| 2013 | Dethorey et al. [ | 2005–2011 | France | 268 | 45 | 50.4 | CL (48.1), OSD (33.7), POS (17.5) |
| 2018 | Ferreira et al. [ | 2007–2015 | Portugal | 235 | 50.0 ± 20.7 | 55.1 | CL (28.9), trauma (28.9), DM (13) |
| 2020 | Sagerfors et al. [ | 2004–2014 | Sweden | 398 | 49.5 | 57 | CL (45.5), OSD (9.8), corneal transplant (9.5) |
| 2010 | Jeng et al. [ | 1998–1999 | US | 302 | 42.8 | 57.3 | CL (55), OSD (19.2), trauma (11.9) |
| 2011 | Keay et al. [ | 2001–2007 | US | 733 | 47.9 | 46.8 | CL (36.6), OSD (28.5), trauma (24.6) |
| 2013 | French et al. [ | 2010 | US | 2124 | 39.2 | 53.5 | Scleral ectasia (4.8), CL (4.8), corneal abrasion (3.1) |
| 2015 | Truong et al. [ | 2009–2014 | US | 318 | 42.9 | 40.3 | CL (41), OSD (28), trauma (17), topical steroid (4) |
| 2011 | Cariello et al. [ | 1975–2007 | Brazil | 16742 | 42.1 ± 21.4 | 40 | POS (22.4), CL (12.8), trauma (16.4), topical steroid (6.6) |
| 2016 | Yu et al. [ | 1975–2010 | Brazil | 859 | – | 42.1 | Topical medication (30.6), Trauma (24), POS (24), CL (13) |
| 2011 | Kumar et al. [ | 2003–2005 | India | 200 | – | 39 | Trauma (78.5), OSD (12) |
| 2011 | Ganguly et al. [ | 2006–2007 | Nepal | 1880 | – | 40.7 | Trauma (58), topical steroid (12), OSD (6), CL (5) |
| 2012 | Dhakhwa et al. [ | 2007 | Nepal | 414 | – | 42.8 | Farmers (75.4), trauma (33.3), topical steroid (4.1) |
| 2012 | Hussain et al. [ | 2007–2009 | Pakistan | 228 | 42.8 ± 21.9 | 35.1 | Trauma (31.5), POS (8.8), topical steroid (6.6) |
| 2012 | Deorukhkar et al. [ | 2004–2009 | India | 852 | – | 31.7 | Trauma (60.2), FB (15.6), POS (9.5) |
| 2013 | Kaliamurthy et al. [ | 2005–2012 | India | 2170 | 45.7 ± 16.6 | 41.3 | Trauma (64.0), traditional eye medicine (16.9) |
| 2015 | Sitoula et al. [ | 2011 | Nepal | 1644 | 44 ± 16 | 42 | Trauma (60), dacryocystitis (5) |
| 2016 | Pan et al. [ | 2003–2012 | China | 578 | 52.4 | 25.4 | Trauma (54.7), URTI (11.9), DM (8) |
| 2018 | Khor et al. [ | 2012–2014 | Asia | 6563 | 46.0 | 39.2 | Trauma (34.7), CL (10.7), POS (6.8), OSD (4.2) |
| 2018 | Chidambaram et al. [ | 2012–2013 | India | 252 | 50 | 36 | Trauma (71.8), traditional eye medicine (19.0) topical steroid (9.9), DM (6.7) |
| 2018 | Al-Ghafri et al. [ | 2013–2016 | Oman | 304 | 52.2 ± 23.2 | 56.2 | Blepharitis (54.3), trachoma (26.0), Other lid diseases (18.1), CL (17.1), Climate droplet keratopathy (15.5) |
| 2018 | Gautam et al. [ | 2016 | Nepal | 259 | 44.9 | 54.4 | Trauma vegetative material (48), topical steroid (9) |
| 2019 | Tong et al. [ | 2012–2016 | Singapore | 377 | 33.6 ± 17.2 | 53.5 | CL (64.3), OSD (10), trauma (3.9) |
| 2020 | Khor et al. [ | 2010–2016 | Malaysia | 221 | 39.5 | 41.2 | Trauma (49.3), CL (23.1), OSD (5.9) |
| 2013 | Oladigbolu et al. [ | 1995–2005 | Nigeria | 228 | – | 43.4 | Trauma (51.3), traditional eye medication (17.1), topical steroid (5.7) |
| 2014 | Mandour et al. [ | 2010–2013 | Egypt | 340 | – | 41.2 | Trauma (50), POS (14.7), topical steroid (11.8) |
| 2018 | Zbiba et al. [ | 2011–2016 | Tunisia | 230 | – | 40 | OSD (58.7), Trauma (51.3), DM (16), topical steroid (10.9), CL (9.5) |
| 2020 | Khoo et al. [ | 2012–2016 | Australia | 979 | 54.7 ± 21.5 | 48.3 | CL (63), topical steroid (24), OSD (18) |
CL contact lens wear, POS previous ocular surgery, OSD ocular surface diseases, FB foreign bodies, DM diabetes, URTI upper respiratory tract infection.
#The data were based on patients presented to general emergency department; therefore, risk factors might not be accurately documented.
A summary of the in vitro antimicrobial susceptibility and resistance of the causative microorganisms of infectious keratitis.
| Year | Authors | Study period | Region | No. of cases | Antibiotic susceptibility (%)a | ||
|---|---|---|---|---|---|---|---|
| CEP | AMG | FQ | |||||
| 2017 | Tan et al. [ | 2004–2015 | UK | 4229 | 86 (P); 61 (N); | 88 (P); 97 (N) | 83 (P); 91 (N) |
| 2019 | Tavassoli et al. [ | 2006–2017 | UK | 2614 | – | 100 (P); 97.0-100 (N) | 91-100 (P); 97-100 (N) |
| 2020 | Ting et al. [ | 2007–2019 | UK | 1333 | 100 (P); 81 (N) | 95 (P); 98-99 (N) | 90-100 (P); 98-100 (N) |
| 2017 | Tam et al. [ | 2000–2015 | Canada | 2330 | – | 96 (P) | 96 (P) |
| 2018 | Peng et al. [ | 1996–2015 | US | 2203 | – | 50-100 (N) | 85-100 (P); 80-100 (N) |
| 2020 | Asbell et al. [ | 2009–2018 | US | 6091 | – | 97 (MSSA); 62 (MRSA); 94 (MS-CoNS); 71 (MR-CoNS); 97 (N) | 89-90 (MSSA); 26-29 (MRSA); 88-89 (MS-CoNS); 43-49 (MR-CoNS); 93-100 (N) |
| 2013 | Vola et al. [ | 2000–2009 | Brazil | 566 | – | 93 (MSSA); 70 (MRSA) | 96 (MSSA); 62 (MRSA) |
| 2015 | Hernandez-Camarena et al. [ | 2002–2011 | Mexico | 1638 | 18-90 (P); 10-92 (N) | 42-80 (P); 69-98 (N) | 54-100 (P); 87-100 (N) |
| 2013 | Kaliamurthy et al. [ | 2005–2012 | India | 2170 | – | 31-95 (P); 90-93 (N) | 70.4-98 (P); 74-90 (N) |
| 2016 | Hsiao et al. [ | 2003–2012 | Taiwan | 2012 | – | 85-88 (N) | 89 (P); 94 (N) |
| 2019 | Acharya et al. [ | 2015–2017 | India | 1169 | – | 73 (P); 89 (N) | 69 (P); 69 (N) |
| 2019 | Lin et al. [ | 2010–2018 | China | 7229 | 84-91 (P); 68-75 (N) | – | 63-75 (P); 46-75 (N) |
| 2016 | Politis et al. [ | 2002–2014 | Jerusalem | 943 | – | 92-94 (P) | 97-100% (P) |
| 2019 | Cabrera-Aguas et al. [ | 2012–2016 | Australia | 1084 | – | 86-97 (P); 100 (N) | 86-95 (P); 99 (N) |
| 2019 | Green et al. [ | 2005–2015 | Australia | 3182 | – | 92 (P); 96 (N) | 94 (P); 99 (N) |
MSSA Methicillin-sensitive Staphylococcus aureus, MRSA Methicillin-resistant S. aureus, MS-CoNS Methicillin-sensitive coagulase negative staphylococci, MR-CoNS Methicillin-resistant coagulase negative staphylococci.
aAntibiotic susceptibility is reported for Gram-positive bacteria (P) and Gram-negative bacteria (N) against three common classes of antibiotics, namely cephalosporin (CEP), aminoglycoside (AMG) and fluoroquinolone (FQ).
Fig. 1The PRISMA flow chart detailing the process and results of literature search for articles related to infectious keratitis.